Understanding Your Pancreatic Cancer Diagnosis
Insightful Guidance for Your Results
Pancreatic cancer develops in the tissues of the pancreas and can vary in type, location, and aggressiveness. Your pathology report highlights key features such as tumor type, grade, and involvement of nearby structures, helping your care team guide treatment and follow-up.
HONEST Pathology specialists carefully review every part of your pancreatic cancer report, providing clear explanations and supportive guidance. We help you understand what each finding means so you can feel informed and confident in your diagnosis and next steps.
Informed Decisions
Better Conversations
Leave Empowered
Peace of Mind
Guided Next Steps
Ready to Understand Your Diagnosis?
Don’t let confusion hold you back. Schedule an online consultation with our expert pathologists and get clear, personalized answers about your diagnosis — all from the comfort of home.
Frequently Asked Questions
Pancreatic cancer develops in the pancreas, an organ that produces enzymes and hormones like insulin. It often begins in the ducts or cells that make digestive enzymes.
Staging describes how far the cancer has spread. Early-stage tumors may be treated with surgery, while advanced stages often need combined therapies.
The most common type is pancreatic ductal adenocarcinoma. Identifying the type helps your care team select the most effective surgical or medical treatments.
Tumor grade shows how abnormal the cancer cells appear under a microscope. High-grade tumors often grow faster and may require more intensive therapy.
Lymph nodes removed during surgery are examined for cancer cells. Involvement helps determine stage and guides treatment decisions.
Biomarkers like CA 19-9 can help monitor treatment response, detect recurrence, and provide additional information about tumor behavior.
Clear surgical margins mean no cancer cells are present at the edges of removed tissue. Positive margins may require additional therapy to reduce recurrence risk.
Yes. Genetic testing may identify mutations like BRCA, which can guide targeted therapy or enrollment in clinical trials.
